Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | SCN1A | P35498 | 5/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 5/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 5/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19970123 | 0.88 | SCN9A (0.39) | SCN9ASCN1ASCN8ATP53KMO | |
| SCHEMBL19968866 | 0.87 | SCN9A (0.39) | SCN9ASCN1ASCN8ATP53KMO | |
| SCHEMBL19925424 | 0.86 | ITGB2 (0.38) | SCN1ASCN8A | |
| SCHEMBL29464387 | 0.86 | ITGB2 (0.38) | SCN1ASCN8A | |
| SCHEMBL19925422 | 0.86 | ITGB2 (0.38) | SCN1ASCN8A | |
| SCHEMBL19925788 | 0.86 | ITGB2 (0.38) | SCN1ASCN8A | |
| SCHEMBL29464328 | 0.86 | ITGB2 (0.38) | SCN1ASCN8A | |
| SCHEMBL22323499 | 0.86 | S1PR1 (0.38) | SCN1ASCN8AS1PR1 | |
| SCHEMBL19951401 | 0.86 | SCN9A (0.33) | SCN9ASCN1ASCN8AS1PR1 | |
| SCHEMBL19925421 | 0.86 | SCN9A (0.33) | SCN9ASCN1ASCN8AS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | disclosed |